Abbott Laboratories

D

Quotes are delayed by 15 minutes

Abbott Laboratories (ABT) trades at 115.55 USD, +5.61% today. Over the last 52 weeks it has traded between 81.97 and 132.03.

Abbott Laboratories trades on NYSE under the ticker ABT.

Abbott Laboratories's share price has fallen 8.2% over the last 12 months. Since the start of the year it is -8.2%.

$1,000 invested in Abbott Laboratories on 4 November 2016 would be worth $3,566 on 4 November 2026, with its dividends reinvested: 13.6% a year. The same in SPY (the S&P 500) would be $4,305, in QQQ (the Nasdaq 100) $6,524.

Abbott Laboratories's beta is 0.54: its price has moved less than the US market as a whole.

At today's price Abbott Laboratories is worth 199.95B USD. Market cap history

Abbott Laboratories's P/E of 42.8 is near the top of its 5-year range (13.2 to 42.8, median 29.7). It is within 5% of its 5-year high. Analysts expect faster growth than in recent years, which can explain part of the high P/E. Fair value is not a reliable guide for Abbott Laboratories: its earnings swing (EPS fell ⁦51.3%⁩ in FY2025), so its usual P/E would mislead. P/E history

Abbott Laboratories earned 2.70 a share over the last twelve months. At today's price its shares trade at 42.8 times those earnings. EPS history

In Q3 FY2026, reported on 21 October 2026, revenue was 13.01B USD and net income 920.00M USD. Revenue was +14.5% on the same quarter a year before. EPS of 1.42 matched the 1.42 analysts expected. Every earnings report

Abbott Laboratories reports its next results on 28 January 2027. Earnings and estimates

The shares moved -2.1% on the trading day after its Q3 FY2026 report on 21 October 2026. Every report and its move

Yes: 2.52 USD a share a year at its current rate, a 2.18% yield at today's price. Dividend history and dates

The last ex-dividend date was 15 October 2026, with the dividend paid on 16 November 2026; the next has not been declared yet. Every dividend and its dates

20 of the 21 firms that rate Abbott Laboratories say buy, 1 hold and 0 sell. Their average 12-month price target is 121.36. Forecast and price targets

Abbott Laboratories spent 1.83B USD buying back its own shares over the last twelve months. Its diluted share count fell 0.1% in fiscal year 2025. Buyback history

Over the last twelve months Abbott Laboratories's insiders made 11 open-market sales of 410,494 shares for 47.54M USD, and 6 purchases. The CEO, Robert Ford, sold 398,832 of them. Every insider trade

Abbott Laboratories has split its stock 9 times: 2-for-1 (1975), 2-for-1 (1978), 2-for-1 (1981), 2-for-1 (1986), 2-for-1 (1990), 2-for-1 (1992), 2-for-1 (1998), 2500-for-2339 (2004), 5000-for-2399 (2013). The last was a 5000-for-2399 split on 2 January 2013. A split adds shares without changing what the company is worth.

Abbott Laboratories is in the Healthcare sector, in the Medical - Devices industry. Company profile

Yes. Abbott Laboratories stock is halal by the AAOIFI Shariah screen, on its latest figures: its business (Medical - Devices) is not an excluded activity, its debt is 16.3% of its market value and its cash and interest-bearing investments 3.4% (the limit is 30% each), and its interest income is 0.5% of its revenue (the limit is 5%). Scholars and screening methods differ.

Through a broker that trades on NYSE: open and fund an account, search for ABT and place an order. Arincen compares regulated brokers in its broker reviews.